CYP3A4*22 (c.522-191 C>T; Rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults

Pharmacogenetics and Genomics

Volumn 24, Issue 9, 2014, Pages 459-463

  Olagunju, Adeniyi ^a,b   Schipani, Alessandro ^a   Siccardi, Marco ^a   Egan, Deirdre ^a   Khoo, Saye ^a   Back, David ^a   Owen, Andrew ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

Author keywords

CYP3A4*22; dose reduction; lopinavir; population pharmacokinetics modelling; rs35599367; SLCO1B1 521TC

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOCHROME P450 3A4; GENOMIC DNA; LOPINAVIR PLUS RITONAVIR; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR; ORGANIC ANION TRANSPORTER; SLCO1B1 PROTEIN, HUMAN;

AGED; ALLELE; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG MONITORING; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ADULT; GENETIC VARIATION; GENETICS; HIV INFECTIONS; MIDDLE AGED;

ADULT; AGED; CYTOCHROME P-450 CYP3A; FEMALE; GENETIC VARIATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LOPINAVIR; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84906060907     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000073     Document Type: Article

References (28)

1. Klein K, Zanger UM. Pharmacogenomics of cytochrome P450 3A4: Recent progress toward the "missing heritability" problem. Front Genet 2013; 4:12
2. Danielson PB. The cytochrome P450 superfamily: Biochemistry, evolution and drug metabolism in humans. Curr Drug Metab 2002; 3:561-597
3. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270:414-423
4. Penno MB, Dvorchik BH, Vesell ES. Genetic variation in rates of antipyrine metabolite formation: A study in uninduced twins. Proc Natl Acad Sci USA 1981; 78:5193-5196
5. Ozdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba AD. Evaluation of the genetic component of variability in CYP3A4 activity: A repeated drug administration method. Pharmacogenetics 2000; 10:373-388
6. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 2011; 11:274-286
7. Lakhman SS, Ma Q, Morse GD. Pharmacogenomics of CYP3A: Considerations for HIV treatment. Pharmacogenomics 2009; 10:1323-1339
8. Koudriakova T, Iatsimirskaia E, Utkin I, Gangl E, Vouros P, Storozhuk E, et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 1998; 26:552-561
9. Hartkoorn RC, Kwan WS, Shallcross V, Chaikan A, Liptrott N, Egan D, et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 2010; 20:112-120
10. Lubomirov R, di Iulio J, Fayet A, Colombo S, Martinez R, Marzolini C, et al. Swiss HIV Cohort Study. ADME pharmacogenetics: Investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics 2010; 20:217-230
11. Kohlrausch FB, De Cássia Estrela R, Barroso PF, Suarez-Kurtz G. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. Br J Clin Pharmacol 2010; 69:95-98
12. Siccardi M, DAvolio A, Baietto L, Gibbons S, Sciandra M, Colucci D, et al. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-T) with reduced concentrations of unboosted atazanavir. Clin Infect Dis 2008; 47:1222-1225
13. Elens L, Bouamar R, Hesselink DA, Haufroid V, Van Der Heiden IP, Van Gelder T, Van Schaik RH. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 2011; 57:1574-1583
14. Elens L, Hesselink DA, Van Schaik RH, Van Gelder T. The CYP3A4. *22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations. Br J Clin Pharmacol 2013; 75:1545-1547
15. Elens L, Capron A, Van Schaik RH, De Meyer M, De Pauw L, Eddour DC, et al. Impact of CYP3A4. *22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: Toward updated genotype-based dosage guidelines. Ther Drug Monit 2013; 35:608-616
16. Gijsen VM, Van Schaik RH, Elens L, Soldin OP, Soldin SJ, Koren G, De Wildt SN. CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients. Pharmacogenomics 2013; 14:1027-1036
17. Elens L, Van Gelder T, Hesselink DA, Haufroid V, Van Schaik RH. CYP3A4*22: Promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics 2013; 14:47-62
18. Elens L, Van Schaik RH, Panin N, De Meyer M, Wallemacq P, Lison D, et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics 2011; 12:1383-1396
19. Elens L, Becker ML, Haufroid V, Hofman A, Visser LE, Uitterlinden AG, et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet Genomics 2011; 21:861-866
20. Elens L, Nieuweboer A, Clarke SJ, Charles KA, De Graan AJ, Haufroid V, et al. CYP3A4 intron 6 CT SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics 2013; 14:137-149
21. Elens L, Tyteca D, Panin N, Courtoy P, Lison D, Demoulin JB, Haufroid V. Functional defect caused by the 4544GA SNP in ABCC2: Potential impact for drug cellular disposition. Pharmacogenet Genomics 2011; 21:884-893
22. Elens L, Yombi JC, Lison D, Wallemacq P, Vandercam B, Haufroid V. Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients. Pharmacogenomics 2009; 10:1589-1597
23. Schipani A, Egan D, Dickinson L, Davies G, Boffito M, Youle M, et al. Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults. Antivir Ther 2012; 17:861-868
24. Flicek P, Ahmed I, Amode MR, Barrell D, Beal K, Brent S, et al. Ensembl 2013. Nucleic Acids Res 2013; 41 (Database issue):D48-D55
25. La Porte C, Back D, Blaschke T, Boucher C, Fletcher C, Flexner C. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev Antiviral Ther 2006; 3:4-14
26. Li F, Lu J, Ma X. CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir. Drug Metab Dispos 2012; 40:18-24
27. Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al. CASTLE Study Team. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010; 53:323-332
28. Malan N, Su J, Mancini M, Yang R, Wirtz V, Absalon J, McGrath D. CASTLE Study Team. Gastrointestinal tolerability and quality of life in antiretroviralnaive HIV-1-infected patients: Data from the CASTLE study. AIDS care 2010; 22:677-686